已收盘 02-06 16:00:00 美东时间
+6.200
+2.58%
Westinghouse Air Brake (WAB) declares $0.31/share quarterly dividend, 24% increase from prior dividend of $0.25. Forward yield 0.5% Payable March 2; for shareholders of record Feb. 17; ex-div Feb. 17....
今天 05:26
Union Pacific and WAB announce historic $1.2B AC4400 upgrade program, cutting fuel use by 5%, boosting tractive effort 14%, and improving reliability by 80%.
02-05 02:54
BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500, Nasdaq and the Dow fell, as the market still grappled wi
02-05 02:42
Wabtec Corporation Files Initial Statement of Beneficial Ownership for Sameer Gaur, President of Global Freight Services Wabtec Corporation – Westinghouse Air Brake Technologies Corporation has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commissi
02-04 08:19
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02
Susquehanna analyst Bascome Majors maintains Westinghouse Air Brake (NYSE:WAB) with a Positive and raises the price target from $240 to $280.
01-27 01:12
Team, Inc. announces Keith Tucker's retirement after 20 years and appoints Gary Hill as CEO effective Feb. 1, 2026. Hill, with over 30 years in industrial services, succeeds Tucker, who steered the company through post-COVID challenges. The Board highlights Hill's proven leadership and experience, confident he will drive growth and margins. Team, Inc., a global provider of specialty industrial services, reaffirms its 2025 outlook.
01-26 22:00
今日重点评级关注:HC Wainwright & Co.:维持Rezolve AI"买入"评级,目标价从10美元升至12美元;HC Wainwright & Co.:维持Largo"买入"评级,目标价从2.9美元升至3.1美元
01-15 16:10
今日重点评级关注:HC Wainwright & Co.:维持Enlivex Therapeutics"买入"评级,目标价从7美元升至13美元;BTIG:维持Oruka Therapeutics"买入"评级,目标价从63美元升至73美元
01-13 10:18
今日重点评级关注:Needham:维持Cartesian Therapeutics"买入"评级,目标价从40美元升至42美元;Piper Sandler:维持Acrivon Therapeutics"超配"评级,目标价从6美元升至8美元
01-12 14:09